Charting the path to better lung cancer care in colombia
NCT ID NCT07703631
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study looks back at medical records of people in Colombia diagnosed with early-stage non-small cell lung cancer between 2017 and 2023. Researchers aim to understand how patients are diagnosed, how long it takes to start treatment, and what factors affect their care. By mapping these patterns, the study hopes to identify gaps and improve outcomes for future patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 267 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study sample will include patients ≥ 18 years old, newly diagnosed with resectable stage IA, IB, II, IIIA, and IIIB NSCLC from January 1st, 2017, to December 31st, 2023, in at least four healthcare institutions selected in Colombia. The ICD-10 code to identify the patients in the study will be from C33X to C3492 corresponding to lung cancer
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee to ensure that the subject qualifies for the study. 1. Patients ≥ 18 years old 2. Patients diagnosed with NSCLC (stage IA, IB, II, IIIA, and IIIB) 3. Clinical records available Exclusion Criteria: 1. Patients with another primary tumor diagnosed (synchronic tumor) 2. Patients from insurances regimens other than the public and private system. 3. Patients with advanced/metastatic disease 4. Patients diagnosed with resectable stage IA, IB, II, IIIA, and IIIB NSCLC in Colombia that went under immunotherapy treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hospital Universitario San Ignacio
RECRUITINGBogotá, Colombia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink advanced solid tumors?
- A spoonful of olive oil before lung surgery: a new shield against a rare complication?
- Can a targeted drug delivery system shrink lung tumors?
- Can a new drug shrink tumors that resist standard care?
- Mobile lung cancer clinics aim to close rural screening gap
- Can protein patterns in stored tumors point to new treatment targets?